176 related articles for article (PubMed ID: 36977486)
1. Trapoxin A Analogue as a Selective Nanomolar Inhibitor of HDAC11.
Ho TT; Peng C; Seto E; Lin H
ACS Chem Biol; 2023 Apr; 18(4):803-809. PubMed ID: 36977486
[TBL] [Abstract][Full Text] [Related]
2. Activity-Guided Design of HDAC11-Specific Inhibitors.
Son SI; Cao J; Zhu CL; Miller SP; Lin H
ACS Chem Biol; 2019 Jul; 14(7):1393-1397. PubMed ID: 31264832
[TBL] [Abstract][Full Text] [Related]
3. HDAC11 regulates type I interferon signaling through defatty-acylation of SHMT2.
Cao J; Sun L; Aramsangtienchai P; Spiegelman NA; Zhang X; Huang W; Seto E; Lin H
Proc Natl Acad Sci U S A; 2019 Mar; 116(12):5487-5492. PubMed ID: 30819897
[TBL] [Abstract][Full Text] [Related]
4. Garcinol Is an HDAC11 Inhibitor.
Son SI; Su D; Ho TT; Lin H
ACS Chem Biol; 2020 Nov; 15(11):2866-2871. PubMed ID: 33034447
[TBL] [Abstract][Full Text] [Related]
5. Histone Deacetylase 11 Is an ε-N-Myristoyllysine Hydrolase.
Moreno-Yruela C; Galleano I; Madsen AS; Olsen CA
Cell Chem Biol; 2018 Jul; 25(7):849-856.e8. PubMed ID: 29731425
[TBL] [Abstract][Full Text] [Related]
6. Binding of the Microbial Cyclic Tetrapeptide Trapoxin A to the Class I Histone Deacetylase HDAC8.
Porter NJ; Christianson DW
ACS Chem Biol; 2017 Sep; 12(9):2281-2286. PubMed ID: 28846375
[TBL] [Abstract][Full Text] [Related]
7. Stabilizing HDAC11 with SAHA to assay slow-binding benzamide inhibitors.
Tian Y; Lv W; Li X; Wang C; Wang D; Wang PG; Jin J; Shen J
Bioorg Med Chem Lett; 2017 Jul; 27(13):2943-2945. PubMed ID: 28501514
[TBL] [Abstract][Full Text] [Related]
8. Development of a novel histone deacetylase inhibitor unveils the role of HDAC11 in alleviating depression by inhibition of microglial activation.
Baek SY; Lee J; Kim T; Lee H; Choi HS; Park H; Koh M; Kim E; Jung ME; Iliopoulos D; Lee JY; Kim J; Lee S
Biomed Pharmacother; 2023 Oct; 166():115312. PubMed ID: 37567072
[TBL] [Abstract][Full Text] [Related]
9. Histone Deacetylase 11 Is a Fatty-Acid Deacylase.
Kutil Z; Novakova Z; Meleshin M; Mikesova J; Schutkowski M; Barinka C
ACS Chem Biol; 2018 Mar; 13(3):685-693. PubMed ID: 29336543
[TBL] [Abstract][Full Text] [Related]
10. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin.
Furumai R; Komatsu Y; Nishino N; Khochbin S; Yoshida M; Horinouchi S
Proc Natl Acad Sci U S A; 2001 Jan; 98(1):87-92. PubMed ID: 11134513
[TBL] [Abstract][Full Text] [Related]
11. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family.
Gao L; Cueto MA; Asselbergs F; Atadja P
J Biol Chem; 2002 Jul; 277(28):25748-55. PubMed ID: 11948178
[TBL] [Abstract][Full Text] [Related]
12. HDAC11: a multifaceted histone deacetylase with proficient fatty deacylase activity and its roles in physiological processes.
Núñez-Álvarez Y; Suelves M
FEBS J; 2022 May; 289(10):2771-2792. PubMed ID: 33891374
[TBL] [Abstract][Full Text] [Related]
13. Development and Pharmacochemical Characterization Discover a Novel Brain-Permeable HDAC11-Selective Inhibitor with Therapeutic Potential by Regulating Neuroinflammation in Mice.
Bai P; Liu Y; Yang L; Ding W; Mondal P; Sang N; Liu G; Lu X; Ho TT; Zhou Y; Wu R; Birar VC; Wilks MQ; Tanzi RE; Lin H; Zhang C; Li W; Shen S; Wang C
J Med Chem; 2023 Dec; 66(23):16075-16090. PubMed ID: 37972387
[TBL] [Abstract][Full Text] [Related]
14. Identification of potential HDAC11 deacylase substrates by affinity pulldown MS.
Zhang Y; Zhao Q; Lin H
Methods Enzymol; 2023; 685():43-55. PubMed ID: 37245910
[TBL] [Abstract][Full Text] [Related]
15. HDAC11 is a novel drug target in carcinomas.
Deubzer HE; Schier MC; Oehme I; Lodrini M; Haendler B; Sommer A; Witt O
Int J Cancer; 2013 May; 132(9):2200-8. PubMed ID: 23024001
[TBL] [Abstract][Full Text] [Related]
16. Utilization of AlphaFold models for drug discovery: Feasibility and challenges. Histone deacetylase 11 as a case study.
Baselious F; Robaa D; Sippl W
Comput Biol Med; 2023 Dec; 167():107700. PubMed ID: 37972533
[TBL] [Abstract][Full Text] [Related]
17. Zinc-dependent histone deacetylases: Potential therapeutic targets for arterial hypertension.
Kee HJ; Kim I; Jeong MH
Biochem Pharmacol; 2022 Aug; 202():115111. PubMed ID: 35640713
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase as a new target for cancer chemotherapy.
Yoshida M; Furumai R; Nishiyama M; Komatsu Y; Nishino N; Horinouchi S
Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S20-6. PubMed ID: 11587361
[TBL] [Abstract][Full Text] [Related]
19. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
[TBL] [Abstract][Full Text] [Related]
20. Unraveling HDAC11: Epigenetic orchestra in different diseases and structural insights for inhibitor design.
Khatun S; Prasad Bhagat R; Dutta R; Datta A; Jaiswal A; Halder S; Jha T; Amin SA; Gayen S
Biochem Pharmacol; 2024 Jul; 225():116312. PubMed ID: 38788962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
